Table 2.

Results of 11q13 LOH and X-Chromosome Inactivation Analysis in 15 Leiomyomata from Five Patients with MEN1

Patient no.	Tumor site	Tumor no.	D11S480*	PYGM†	D11S449	INT-2	HUMARA‡
1	Esophagus	T1	•	NI	NI	•	—
2	Esophagus	T2	•	•	•	•	—
	Esophagus	T3	•	•	•	•	—
3	Uterus	T4	•	NI	•	NI	Monoclonal(U)
	Uterus	T5	•	NI	•	NI	Monoclonal(L)
	Uterus	T6		NI		NI	Monoclonal(L)
4	Lung	T7	NI			NI	Monoclonal(U)
	Lung	T8	NI			NI	Monoclonal(U)
	Lung	T9	NI			NI	Monoclonal(U)
	Esophagus	T10	Ni			NI	Polyclonal (U, L)
	Uterus	T11	NI	•	•	NI	Monoclonal(U)
	Uterus	T12	NI	•		NI	Monoclonal(L)
	Uterus	T13	NI	•	•	NI	Monoclonal(L)
5§	Esophagus	T14	NI	•	•	NI	—
	Esophagus	T15	NI	•	•	NI	—

•, LOH; , retention of heterozygosity; NI, noninformative; —, not done.

*Chromosome 11q13 polymorphic markers at the MEN1 locus are listed in order from centromeric (left) to telomeric (right), MEN1 is between PYGM and D11S449.

^†Marker PYGM(CAGA) in Patients 1 and 3, and marker PYGM(AT) in patients 4 and 5.

^‡Monoclonal(U), only upper allele methylation in tumor as compared to normal tissue; monoclonal(L), only lower allele methylation in tumor as compared to normal tissue; polyclonal(U,L), both upper and lower alleles methylated in tumor.

^§LOH data in two esophageal leiomyomata in patient 5 were previously reported,14 and reanalyzed and confirmed in this study.